MASTERINVEST Kapitalanlage GmbH Buys New Stake in Stryker Corporation $SYK

MASTERINVEST Kapitalanlage GmbH purchased a new position in shares of Stryker Corporation (NYSE:SYK) in the second quarter, HoldingsChannel reports. The institutional investor purchased 9,147 shares of the medical technology company’s stock, valued at approximately $2,880,000.

Other large investors have also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in Stryker in the fourth quarter valued at about $1,822,272,000. Bank of America Corp DE purchased a new stake in shares of Stryker in the second quarter worth about $1,404,284,000. Auto Owners Insurance Co grew its stake in shares of Stryker by 35,047.0% in the fourth quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock valued at $1,024,444,000 after buying an additional 2,906,448 shares in the last quarter. Legal & General Group Plc acquired a new stake in shares of Stryker in the second quarter valued at about $707,212,000. Finally, Jupiter Topco LLC purchased a new stake in shares of Stryker during the 2nd quarter valued at about $681,581,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SYK has been the topic of several recent research reports. Citizens Jmp reduced their price target on Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a research report on Monday, August 3rd. Barclays lowered their price objective on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research report on Monday, May 4th. Canaccord Genuity Group reduced their target price on shares of Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Wolfe Research downgraded shares of Stryker from an “outperform” rating to a “peer perform” rating in a research note on Thursday, August 13th. Finally, Needham & Company LLC lowered their price target on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $386.28.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 50,000 shares of the business’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total value of $17,005,000.00. Following the completion of the sale, the director owned 2,251,375 shares of the company’s stock, valued at approximately $765,692,637.50. The trade was a 2.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Debra King sold 826 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares of the company’s stock, valued at $2,088,423. The trade was a 11.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 351,267 shares of company stock valued at $118,197,701 over the last ninety days. Corporate insiders own 4.60% of the company’s stock.

Stryker Price Performance

Shares of NYSE SYK opened at $322.20 on Friday. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86. The business has a 50 day moving average price of $328.64 and a two-hundred day moving average price of $331.47. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The firm has a market cap of $123.58 billion, a PE ratio of 33.39, a price-to-earnings-growth ratio of 2.10 and a beta of 0.76.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the company posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts expect that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio is currently 36.48%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.